Opinion|Videos|October 18, 2024
Safety and Efficacy of RSV Vaccines in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Key Takeaways
- ConquerRSV, AReSVi-006, and RENOIR trials show significant efficacy in preventing RSV-related illness in older adults.
- The vaccines have demonstrated generally well-tolerated safety profiles with manageable side effects.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide an overview of the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.
Advertisement
Related to this article
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
For as long as practicing oncology pharmacists have been in the field, multiple myeloma has carried a standard caveat: treatable, not curable. Now that is changing.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5